Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

ClinicalTrials.gov ID: NCT06043674

Public ClinicalTrials.gov record NCT06043674. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Glofitamab as Monotherapy or in Combination With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in this research study are: * Glofitamab (a T-cell bispecific humanized monoclonal antibody) * Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody) * Polatuzumab vedotin (an antibody-drug conjugate) * Pirtobrutinib (a selective inhibitor of BTK) * Atezolizumab (a humanized immunoglobulin monoclonal antibody) * Tocilizumab (a recombinant, humanized, anti-human monoclonal antibody)

Study identification

NCT ID: NCT06043674
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Christine Ryan; Other
Enrollment: 70 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 21, 2024
Primary completion: Jan 14, 2028
Completion: Jan 14, 2033
Last update posted: Jan 6, 2026

2024 – 2033

United States locations

U.S. sites: 5
U.S. states: 4
U.S. cities: 4

Facility	City	State	ZIP	Site status
Winship Cancer Institute at Emory University	Atlanta	Georgia	30322	Recruiting
Brigham and Women's Hospital	Boston	Massachusetts	02215	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
The University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	Recruiting
The Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06043674, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 6, 2026 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06043674 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →